Inhibiting SLC38A2 lowers blood pressure in rodent models of hypertension.

Summary

This mechanistic study identifies the endothelial amino acid transporter SLC38A2 as a blood pressure regulator via nitric oxide signaling. Genetic manipulation of SLC38A2 in mice and endothelial cells and pharmacologic inhibition reduced blood pressure in hypertensive rodent models, highlighting a druggable pathway for hypertension.

Key Findings

• SLC38A2 was identified as an endothelial regulator of blood pressure via nitric oxide signaling.
• Global and endothelial cell–specific perturbation of SLC38A2 in mice altered blood pressure.
• Pharmacologic inhibition of SLC38A2 lowered blood pressure in rodent hypertension models.

Clinical Implications

While preclinical, targeting SLC38A2 or its downstream NO signaling could yield first-in-class antihypertensives, especially for resistant hypertension. It also supports integrating endothelial amino acid transport into vascular health paradigms.

Limitations

• Preclinical animal work without human validation
• Incomplete safety, selectivity, and long-term efficacy data for SLC38A2 inhibitors

Future Directions

Validate SLC38A2 mechanisms in human endothelium and genetics, develop selective inhibitors, and test efficacy/safety in early-phase hypertension trials.